- Home
- MOLN vs DOUG Comparison
MOLN vs DOUG Comparison
Compare MOLN & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- DOUG
- Stock Information
- Founded
- MOLN 2004
- DOUG 1911
- Country
- MOLN Switzerland
- DOUG United States
- Employees
- MOLN N/A
- DOUG N/A
- Industry
- MOLN
- DOUG Building operators
- Sector
- MOLN
- DOUG Real Estate
- Exchange
- MOLN Nasdaq
- DOUG Nasdaq
- Market Cap
- MOLN 142.6M
- DOUG 161.5M
- IPO Year
- MOLN 2021
- DOUG N/A
- Fundamental
- Price
- MOLN $3.67
- DOUG $2.66
- Analyst Decision
- MOLN
- DOUG
- Analyst Count
- MOLN 0
- DOUG 0
- Target Price
- MOLN N/A
- DOUG N/A
- AVG Volume (30 Days)
- MOLN 1.1K
- DOUG 664.6K
- Earning Date
- MOLN 09-05-2025
- DOUG 07-31-2025
- Dividend Yield
- MOLN N/A
- DOUG N/A
- EPS Growth
- MOLN N/A
- DOUG N/A
- EPS
- MOLN N/A
- DOUG N/A
- Revenue
- MOLN $2,525,030.00
- DOUG $1,034,406,000.00
- Revenue This Year
- MOLN N/A
- DOUG $17.61
- Revenue Next Year
- MOLN $1,000.00
- DOUG N/A
- P/E Ratio
- MOLN N/A
- DOUG N/A
- Revenue Growth
- MOLN N/A
- DOUG 8.69
- 52 Week Low
- MOLN $3.36
- DOUG $1.35
- 52 Week High
- MOLN $7.60
- DOUG $3.20
- Technical
- Relative Strength Index (RSI)
- MOLN 52.01
- DOUG 57.02
- Support Level
- MOLN $3.53
- DOUG $2.40
- Resistance Level
- MOLN $3.59
- DOUG $2.56
- Average True Range (ATR)
- MOLN 0.07
- DOUG 0.15
- MACD
- MOLN 0.00
- DOUG 0.03
- Stochastic Oscillator
- MOLN 43.75
- DOUG 96.49
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.